BOSTON, MASS., May 12, 2025 – BPGbio Inc., a biology-first, AI-powered clinical-stage biopharma company, announced today that its General Counsel, Ritesh Srivastava, has been named a shortlisted nominee for the 2025 Los Angeles Times Executive Leadership Awards. Mr. Srivastava is recognized in the In-House Counsel category for his exemplary legal leadership, commitment to mission-driven innovation, and broad impact across the biopharmaceutical and legal sectors.
The Los Angeles Times Executive Leadership Awards, presented by LA Times Studios, honor outstanding senior executives in California who are shaping the future of their industries through bold leadership, community engagement, and lasting contributions to business and society. Honorees and winners will be celebrated at a live event at the Fairmont Miramar in Santa Monica on May 12, 2025.
A U.S. Navy veteran, former DOJ trial attorney, and seasoned biotech legal executive, Mr. Srivastava brings nearly two decades of experience to his role at BPGbio. His diverse background spans international law, healthcare fraud prosecution, corporate transactions and governance, and ESG leadership. At BPGbio, he has played a pivotal role in advancing business development initiatives, protecting a global patent portfolio of over 400 patents, and enabling strategic partnerships that support the company’s leadership in AI-driven drug discovery.
“Ritesh is a true mission-first leader whose legal insight and strategic vision help drive BPGbio forward every day,” said Dr. Niven Narain, President and CEO of BPGbio. “He combines deep legal expertise with a business mindset and an unwavering commitment to ethical leadership. We are proud to see him recognized for the exceptional impact he’s making both within BPGbio and across the broader community.”
Mr. Srivastava has held senior legal roles at Spectrum Pharmaceuticals and Avanir Pharmaceuticals, leading corporate transactions, M&A, Compliance and ESG initiatives. A committed public servant, he has served on the boards of the South Asian Bar Association’s Public Interest Foundation and the Albert Schweitzer Fellowship. He holds a B.S. from Columbia University and a J.D. from Pepperdine Law. He is based in Los Angeles, CA, where he continues to champion innovation and inclusion across the legal and biotech sectors.
About BPGbio
BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com.
Media Contact: media@bpgbio.com
